In China, pazopanib was approved for market on March 3, 2017; The National Medical Products Administration (NMPA) has approved pazopanib for first-line treatment of advanced renal cell carcinoma patients and advanced renal cancer patients who have received cytokine therapy.

1、 Drug name

1. Common name: pazopanib

2. Product Name: VOTRIENT

2、 Indications

Used to treat patients with advanced renal cell carcinoma (RCC).

3、 Specifications and characteristics

200mg、 Tablets.

4、 Usage and dosage

1. Recommended dosage: 800mg orally, once daily.

2. Medication time: Take on an empty stomach (1 hour before or 2 hours after meals).

3. Cannot be crushed and taken (may increase absorption rate and affect efficacy).

5、 Dose adjustment

1. Liver dysfunction: reduce to 200mg/day for moderate liver dysfunction patients; Prohibited for individuals with severe liver function impairment.

2. Drug interactions:

When combined with strong CYP3A4 inhibitors (such as ketoconazole), reduce to 400mg.

Strong CYP3A4 inducers (such as rifampicin) should be avoided in combination.

3. Other adjustments: Adjust in increments of 200mg based on tolerance, with a maximum dose not exceeding 800mg.

6、 Medication precautions

1. Dietary impact: Both high-fat and low-fat diets can increase blood drug concentrations by 2 times and must be taken on an empty stomach.

2. Omission treatment: If it is less than 12 hours before the next medication, skip it and do not make up for it.

3. Vomiting treatment: If vomiting occurs after taking medication, do not take additional medication. Follow the original plan for the next dose.

4. Before and after surgery: Stop medication for at least 7 days before surgery, and determine the time to resume medication after surgery based on the healing of the wound.

7、 Medication for special populations

1. Pregnant women: May cause fetal damage, prohibited during pregnancy (pregnancy grade D).

2. Breastfeeding period: Suspend breastfeeding (unknown if medication is administered).

3. Children: Safety has not been established.

4. Older adults: Patients aged 65 and above need to be closely monitored for liver function.

8、 Adverse reactions

1. Common (≥ 20%): Diarrhea, hypertension, hair loss, nausea, anorexia, vomiting.

2. Serious adverse reactions:

Hepatotoxicity (monitoring ALT/AST), QT interval prolongation (monitoring electrocardiogram), bleeding events (prohibited for those with a history of bleeding within 6 months), arterial thrombosis (risk of myocardial infarction/stroke).

9、 Contraindications

There are no absolute contraindications, but the following situations are prohibited:

1. Severe liver dysfunction.

2. History of cerebral hemorrhage/gastrointestinal bleeding within 6 months.

3. Pregnancy period.

10、 Drug interactions

1. CYP3A4 inhibitors: Avoid using potent inhibitors in combination (such as clarithromycin).

2. CYP3A4 inducer: Avoid using strong inducers (such as rifampicin) in combination.

3. Narrow therapeutic window drugs: Avoid using drugs metabolized by CYP3A4/2D6/2C8 in combination (such as warfarin).

11、 Storage method

Not explicitly stated, it is recommended to follow the standard oral tablet storage method (avoid light, cool and dry place).

pazopaniinformation